Encompass Health Corp Receives Strong Buy Rating, Price Target Raised by Stephens & Co Analyst

Encompass Health Corp (NYSE: EHC) has received a Strong Buy rating from analyst Scott Fidel at Stephens & Co. Fidel also raised the price target for the company from $74.00 to $78.00. This rating and price target adjustment come as Fidel increases his EBITDA estimates for Encompass Health Corporation for the fiscal years 2023 to 2025.

According to Fidel, the decision to maintain a Strong Buy rating and raise the price target is based on the expectation of a stronger Medicare patient demand backdrop in the second quarter. Fidel believes that Encompass Health Corp will benefit from this trend and that the company's ability to respond to rising demand will be enhanced by improving labor supply.

Encompass Health Corp is a leading provider of facility-based and home-based post-acute services. The company operates a network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. Formerly known as Amcare, Inc., Encompass Health was incorporated in 1984 and is headquartered in Birmingham, AL. Their services cater to patients who require specialized care following an acute illness, injury, or surgery.

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen and Don Francis do not hold any positions in the companies mentioned in this article. The information and statistics provided herein are presented for general informational purposes only and may not be accurate, complete, or up-to-date. It should not be interpreted as a recommendation to buy or sell any stocks and should not be solely relied upon for making investment decisions. It does not take into account your financial situation or risk profile. All investors should conduct their own investment due diligence before buying a stock. WallStreetZen expressly disclaims any liability for the accuracy, reliability, or completeness of the analysts' information, price targets, ratings, or opinions.